Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
PaperCitations, authors & open-access status
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 115 citations, 2019 year and bronze oa status.
115
Citations
2019
Year
bronze
OA Status